More News! 26 Jul 2024
Confo Therapeutics raises $60 million to focus on agonistic GPCR antibodies
Discover the field of agonistic GPCR antibodies after Confo therapeutics successfully raised $60 million in its series B round.
Confo Therapeutics
- Latest Posts
News and Trends 3 Mar 2023
Lilly to develop Confo pain drug
Confo Therapeutics, which works on the discovery of medicines targeting G-protein coupled receptors (GPCRs), has announced a worldwide licensing agreement with Eli Lilly and Company for Confo’s clinical stage CFTX-1554 and back-up compounds. CFTX-1554, a novel inhibitor of the angiotensin II type 2 receptor (AT2R) is currently in phase 1 clinical development. It represents a […]
News and Trends 7 May 2019
Belgian Biotech Raises €30M Series A to Unlock Undruggable Targets
Confo Therapeutics has raised €30M in a Series A round that will take its unique technology to find drugs for historically undruggable targets to clinical trials. The fundraising was led by the VCs BioGeneration Ventures and Wellington Partners, and joined by several other private and public investors. With the money, Confo Therapeutics aims to […]
News and Trends 19 Dec 2017
Belgian Biotech and Roche Take on Neurological and Developmental Disorders
Confo Therapeutics has joined forces with Roche to develop new small molecule agonists of a G-protein coupled receptor to treat neurological and developmental disorders. Confo Therapeutics is developing a pipeline of G-protein coupled receptor (GPCR)-targeting drugs to address an unmet medical needs. The biotech spun out from the Vrije Universiteit Brussel in 2015 with the backing of […]
News and Trends 26 Sep 2017
Belgian Biotech Teams Up With Lundbeck to Collaborate on Drug Discovery
Confo and Lundbeck have joined forces to push through drug discovery against a tough-to-target protein using Confo’s special technology. Confo Therapeutics develops small antibody fragments, ‘Confobodies’, that stabilize G-protein coupled receptors (GPCRs). Although Lundbeck has the exclusive license to commercialize compounds from the collaboration, Confo would receive up to €5M in technology fees, plus milestone payments and royalties depending on […]
News and Trends 1 Feb 2017
Young Belgian Biotech will tackle Fibrosis with a New Grant
Confo Therapeutics has received a €1.6M grant to support the discovery of drugs against fibrosis, one of the most deadly conditions in Western countries. Confo Therapeutics is a young biotech in Brussels developing a unique technology to target historically undruggable G protein-coupled receptors (GPCRs). The company just announced it received a €1.6M grant from Flanders Innovation & […]
ADVERTISEMENT
ADVERTISEMENT
News and Trends 23 Nov 2016
These Biotech Veterans have Launched a Startup to ‘Drug the Undruggable’
GPCRs have spelled “dead end” for many a biotech and academic endeavor. I sat down with Confo Therapeutics to hear about how they’re recruiting antibodies for a new onslaught. Despite their allure as the key to many indications, GPCRs are not a target for the faint of heart because they tend to move through a […]
ADVERTISEMENT
